A Phase I/II Study of CX5461
CX5461 is a new type of drug for many types of cancer, particularly cancers that cannot
easily repair damage to their cells. This may help to slow down the growth of cancer or may
cause cancer cells to die. CX5461 has been shown to shrink tumours in animals and has been
studied in a few people and seems promising but it is not clear if it can offer better
results than standard treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society